Article

Government may pick up expenses of your hobby

Consider these nine points to determine if your outside interest qualifiesas a 'business'

Related Videos
1 expert is featured in this series.
Outcomes in Black patients receiving darolutamide plus ADT for mHSPC
2 experts are featured in this series.
Key Benefits of PET in ccRCC Risk Stratification
4 experts in this video
Case 2: A 68-Year-Old Woman With Non–Muscle-Invasive Bladder Cancer
2 experts are featured in this series.
Early Detection of ccRCC
1 expert is featured in this series.
Comparing the safety profile of darolutamide with other androgen receptor inhibitors in Black patients
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
Study findings highlight gender gaps in oncology authorship and citation
NMIBC Treatment Decisions in the Age of BCG Shortages
NMIBC Treatment Decisions in the Age of BCG Shortages
Current Standards of Care and Shifting Strategies in NMIBC
Current Standards of Care and Shifting Strategies in NMIBC
Related Content
Survey: New NMIBC treatments face slow uptake
June 2nd 2025

Survey: New NMIBC treatments face slow uptake

Benjamin P. Saylor
Results of an exclusive Urology Times survey point to urologists preferring intravesical chemotherapy for treating BCG-unresponsive NMIBC.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
FDA updates in urology: May 2025
June 2nd 2025

FDA updates in urology: May 2025

Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from May 2025.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Nivolumab/ipilimumab continues to show improved survival, durable response in aRCC
June 1st 2025

Nivolumab/ipilimumab continues to show improved survival, durable response in aRCC

Hannah Clarke
"This final analysis of this study continues to support nivo+ipi as a standard of care for patients with untreated RCC," says Robert J. Motzer, MD.
Michiel Van der Heijden, MD, PhD
June 1st 2025

Mixed results reported for nivolumab/ipilimumab in cisplatin-ineligible mUC

Benjamin P. Saylor
"The pre-specified thresholds for statistical significance were not met for the dual primary end points of overall survival in cisplatin-ineligible and PD-L1 positive patients," said Michiel Van der Heijden, MD, PhD.
© 2025 MJH Life Sciences

All rights reserved.